LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $14K fell 68.2% year over year, behind the +439.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +530.7% a year.
Context
- Financing cash flow amounted to 784.5% of revenue in FY2025.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -68.2% toward the trailing-twelve-month pace of +439.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 149.75M USD
- Year-over-year change
- -24.8%
- 4-year CAGR
- -22.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 149.75M | -24.8% |
| FY2024 | 2024-12-31 | 199M | +146.6% |
| FY2023 | 2023-12-31 | 80.7M | +13417.6% |
| FY2022 | 2022-12-31 | 597K | -99.9% |
| FY2021 | 2021-12-31 | 417.47M | — |
Financing Cash Flow vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +439.0% is the 3rd highest of 11, against a peer median of +27.8%.
- Financing cash flow amounts to 713.3% of revenue for LENZ, versus a peer median of 91.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $166.3M USD | +4048.1% | +134.0% | — | |
| LTM Jun 2026 | $164.27M USD | -32.1% | -55.5% | 78.7% | |
| LTM Mar 2026 | $149.72M USD | +439.0% | +530.7% | 713.3% | |
| LTM Mar 2026 | $145.91M USD | +227.5% | -5.8% | 3616.9% | |
| LTM Mar 2026 | $135.29M USD | +12.9% | +1065.7% | — | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $104.03M USD | +42.8% | -18.1% | 105.1% |
| LTM Mar 2026 | $103.17M USD | +48.5% | -10.4% | — | |
| FY2025 | €37.42M EUR | +828.6% | — | 126.2% | |
| LTM Mar 2026 | $14.56M USD | -52.0% | -43.6% | 7.6% | |
| LTM Mar 2026 | $4.44M USD | -97.6% | -70.4% | 2.3% | |
| LTM Mar 2026 | $2.23M USD | -101.6% | — | — | |
| Peer median (excluding LENZ) | — | +27.8% | -14.3% | 91.9% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.76M) | (101.05M) | (69.97M) | (49.77M) | (82.13M) |
| Depreciation & Amortization | 734K | 8.35M | 15K | 58K | (3.12M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 1.34M | 6.37M | 12.55M |
| Change in Working Capital | (2.5M) | (7.21M) | 9.41M | (13.09M) | 3.25M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (329K) |
| Inventory | 0 | 0 | 0 | 0 | (4.28M) |
| Accounts Payables | 1.83M | 194K | 856K | (4.28M) | (90K) |
| Other Working Capital | (4.32M) | (7.4M) | 8.55M | (8.81M) | 7.95M |
| Other Non-Cash Items | 19.67M | 11.93M | (1.18M) | (2.95M) | 279K |
| Operating Cash Flow | (52.85M) | (87.98M) | (60.38M) | (59.39M) | (69.17M) |
| Capital Expenditures | (5.74M) | (6.59M) | (30K) | (468K) | (827K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (405.52M) | (52.09M) | (241.91M) | (280.8M) |
| Sales of Investments | 0 | 170.25M | 22.5M | 87.9M | 205.96M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.74M) | (241.86M) | (29.62M) | (154.48M) | (75.67M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 417.16M | 676K | 203K | 79.51M | 149.75M |
| Common Stock Repurchased | 0 | (79K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 306K | 0 | (2.48M) | 119.49M | 0 |
| Financing Cash Flow | 417.47M | 597K | 80.7M | 199M | 149.75M |
| Effect of Forex Changes | (1.72M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 357.16M | (329.25M) | (9.3M) | (14.87M) | 4.91M |
| Free Cash Flow | (58.59M) | (94.57M) | (60.41M) | (59.86M) | (70M) |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.